▲ +72.70% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for InspireMD in the last 3 months. The average price target is $10.50, with a high forecast of $10.50 and a low forecast of $10.50. The average price target represents a 72.70% upside from the last price of $6.08.
The current consensus among 1 contributing investment analysts is to buy stock in InspireMD. This Buy consensus rating has held steady for over two years.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.